Other risk factors, such as patient age, sex, race/ethnicity, hypertension status, dyslipidemia, blood pressure (BP), and use of anti-VEGF therapy, have been assessed, but not all studies agree on which risk factors significantly affect the incidence or progression of DR [10–16]. Here, VEGFA is linked to Hypertension.